文献速递传染病防控与疫情报告免疫规划卫生政策与健康促进

新冠病毒奥密克戎BA.2变异株优势流行期间成人实验室确诊COVID-19相关住院情况——COVID-19相关住院监测网络,14个州,2021年6月20日至2022年5月31日

Laboratory-Confirmed COVID-19-Associated Hospitalizations Among Adults During SARS-CoV-2 Omicron BA.2 Variant Predominance - COVID-19-Associated Hospitalization Surveillance Network, 14 States, June 20, 2021-May 31, 2022.
PubMed 文献 · MMWR Morb Mortal Wkly Rep · 2022-08-26

分析COVID-NET 14个州数据,描述2022年3月20日至5月31日奥密克戎BA.2优势流行期≥18岁成人COVID-19相关住院率。≥65岁成人周住院率从6.9/10万升至27.6/10万,增长三倍;18–49岁和50–64岁均增长1.7倍;未接种疫苗成人住院率为接种者的3.4倍。所有成人应保持COVID-19疫苗接种及时更新。

要点

  • ≥65岁成人周住院率从6.9/10万升至27.6/10万,增长三倍
  • 18–49岁与50–64岁成人住院率同期均增长1.7倍
  • 未接种疫苗成人住院率为接种者的3.4倍

核心结论

  • 奥密克戎BA.2优势流行期成人COVID-19相关住院率上升,未接种疫苗者住院率高于接种者。
  • 所有成人应保持COVID-19疫苗接种及时更新,并采用多种非药物和医学预防措施保护重症高风险人群,无论其疫苗接种状态如何。

研究设计与样本

  • 分析COVID-19相关住院监测网络(COVID-NET)14个州数据,对象为≥18岁成人,观察期为BA.2优势流行期(奥密克戎BA.2和BA.2.12.1;2022年3月20日至5月31日)。

主要发现

  • ≥65岁成人周住院率(每10万人口住院数)从6.9(截至2022年4月2日当周)升至27.6(截至2022年5月28日当周),增长三倍。
  • 18–49岁和50–64岁成人住院率在同一时间间隔内均增长1.7倍。
  • 未接种疫苗成人住院率为接种疫苗成人的3.4倍。
  • 同期住院的非妊娠患者中,39.1%已接种基础免疫程序加1剂加强针或额外剂量,5.0%已接种基础免疫程序加≥2剂加强针或额外剂量。

关键数值与推荐

  • ≥65岁成人周住院率从6.9升至27.6(每10万人口),增长三倍。
  • 18–49岁和50–64岁成人住院率均增长1.7倍。
  • 未接种疫苗成人住院率为接种者的3.4倍。
  • 住院非妊娠患者中39.1%接种基础程序加1剂加强或额外剂量,5.0%接种基础程序加≥2剂加强或额外剂量。

临床怎么用

  • 所有成人应保持COVID-19疫苗接种及时更新。
  • 应使用多种非药物和医学预防措施保护重症高风险人群,无论其疫苗接种状态如何。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Beginning the week of March 20–26, 2022, the Omicron BA.2 variant of SARS-CoV-2, the virus that causes COVID-19, became the predominant circulating variant in the United States, accounting for >50% of sequenced isolates.* Data from the COVID-19–Associated Hospitalization Surveillance Network (COVID-NET) were analyzed to describe recent COVID-19–associated hospitalization rates among adults aged ≥18 years during the period coinciding with BA.2 predominance (BA.2 period [Omicron BA.2 and BA.2.12.1; March 20–May 31, 2022]). Weekly hospitalization rates (hospitalizations per 100,000 population) among adults aged ≥65 years increased threefold, from 6.9 (week ending April 2, 2022) to 27.6 (week ending May 28, 2022); hospitalization rates in adults aged 18–49 and 50–64 years both increased 1.7-fold during the same time interval. Hospitalization rates among unvaccinated adults were 3.4 times as high as those among vaccinated adults. Among hospitalized nonpregnant patients in this same period, 39.1% had received a primary vaccination series and 1 booster or additional dose; 5.0% had received a primary series and ≥2 boosters or additional doses. All adults should stay up to date† with COVID-19 vaccination, and multiple nonpharmaceutical and medical prevention measures should be used to protect those at high risk for severe COVID-19 illness, irrespective of vaccination status§ (1). Beginning the week of March 20–26, 2022, the Omicron BA.2 variant of SARS-CoV-2, the virus that causes COVID-19, became the predominant circulating variant in the United States, accounting for >50% of sequenced isolates.* Data from the COVID-19–Associated Hospitalization Surveillance Network (COVID-NET) were analyzed to describe recent COVID-19–associated hospitalization rates among adults aged ≥18 years during the period coinciding with BA.2 predominance (BA.2 period [Omicron BA.2 and BA.2.12.1; March 20–May 31, 2022]). Weekly hospitalization rates (hospitalizations per 100,000 population) among adults aged ≥65 years increased threefold, from 6.9 (week ending April 2, 2022) to 27.6 (week ending May 28, 2022); hospitalization rates in adults aged 18–49 and 50–64 years both increased 1.7-fold during the same time interval. Hospitalization rates among unvaccinated adults were 3.4 times as high as those among vaccinated adults. Among hospitalized nonpregnant patients in this same period, 39.1% had received a primary vaccination series and 1 booster or additional dose; 5.0% had received a primary series and ≥2 boosters or additional doses. All adults should stay up to date† with COVID-19 vaccination, and multiple nonpharmaceutical and medical prevention measures should be used to protect those at high risk for severe COVID-19 illness, irrespective of vaccination status§ (1).

来源:MMWR Morb Mortal Wkly Rep,查看原文。版权归原作者所有。

引用

  1. Havers FP, Patel K, Whitaker M, et al. Laboratory-Confirmed COVID-19-Associated Hospitalizations Among Adults During SARS-CoV-2 Omicron BA.2 Variant Predominance - COVID-19-Associated Hospitalization Surveillance Network, 14 States, June 20, 2021-May 31, 2022. MMWR Morb Mortal Wkly Rep. 2022. PMID: 36006841. doi:10.15585/mmwr.mm7134a3

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。